Farina Klocksieben

MedicineDecision Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval”.

Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval

Journal of Clinical Epidemiology(2018)10.1016/j.jclinepi.2018.01.011

N/A

2.0DataRank · unranked

42 citations

Paul Glasziou, Farina A. Klocksieben, Tea Reljic, Magali VanDenBergh, Rahul Mhaskar +4 more

US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials

JAMA Network Open(2019)10.1001/jamanetworkopen.2019.11111

N/A

1.5DataRank · unranked

42 citations

Paul Glasziou, Farina A. Klocksieben, John P. A. Ioannidis, Iain Chalmers, Farina Klocksieben +2 more